In patients with unexplained left ventricular hypertrophy and "pseudo-infarction" electrocardiographic patterns, targeted evaluation for FD is warranted to prevent diagnostic delay and enable timely initiation of enzyme replacement therapy (ERT) and multidisciplinary management.
Xie et al. (Tue,) studied this question.